3Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment-a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand, 2002,106: 403-414.
4Pohjasvaara T, Mantyla R, Aronen HJ, et al. Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort. J Neurol Neurosurg Psychiatry, 1999,67:742-748.
5Henon H, Durieu I, Lebert F, et al. Influence of prestroke dementia on early and delayed mortality in stroke patients. J Neurol, 2003,250:10-16.
6McKhann G, Drachman D, Folstein M, et al.Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984 ,34:939-944.
7Roman GC, Tatemichi TK, Erkinjuntti T, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 1993, 43: 250-260.
8Rasquin S, Lodder J, Verhey F.The association between psychiatric and cognitive symptoms after stroke: a prospective study. Cerebrovasc Dis, 2005,19:309-316.
9Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc, 2005,105:145-158.
10Farias GG, Godoy JA, Vazquez MC, et al. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis, 2005,18:176-183.
